The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Using FAERS to Determine Medical Costs – a Payer Perspective

Posted by Brian Overstreet on March 31, 2017

We're happy to have a guest writer on the RxView blog this week, Alan Lukazewski, RPh – Director of Clinical Pharmacy at WEA Trust

WEA Trust is a not-for-profit health insurer serving Wisconsin public employers, their staffs and families.  In my role as Director of Clinical Pharmacy, I manage pharmacy benefits for WEA Trust, including prior authorization management, clinical program design, and specialty pharmacy management.  Within those areas, I focus attention on adverse drug event detection and prevention, especially in older adults. 

Last year, we partnered with Advera Health on a unique project to determine whether we could use data from the FDA Adverse Event Reporting System (FAERS) to determine total medical costs for a particular class of medicines.  Previously, Advera Health published a study detailing their methodology for calculating medical costs from FAERS data, but this would be the first study to pair FAERS data with specific claims data to determine downstream medical costs.

Read More

Topics: FAERS, RxCost, AMCP

Connect with Advera Health at the AMCP 2016 Annual Meeting

Posted by Brian Overstreet on April 19, 2016

In last week's post we wrote about the need for both managed care and pharmaceutical manufacturers to engage in conversation around ways to make pre-approval drug evidence more readily available, and more importantly, actionable. The AMCP Managed Care & Specialty Pharmacy Annual Meeting, taking place at the Moscone West in San Francisco this week is the perfect opportunity to make this happen. 

Read More

Topics: Evidence, AMCP

Payers Need Better Access to Clinical Trial Results Prior to Drug Approval

Posted by Jim Davis on April 15, 2016

Managed Care Organizations are reviewing drugs well before a product is approved. According to a survey conducted by Dymaxium (the company behind the AMCP eDossier System) and presented in a recent webinar, 2 out of 3 healthcare decision makers begin to evaluate a drug at least 6 months prior to approval. The survey also indicates that the primary source of information that payers are using for these pre-approval evaluations is (, and that manufacturers are not always responsive to requests for information pre-approval.

Read More

Topics: Clinical Evidence, AMCP, Evidex

Subscribe to Email Updates